OncWeekly Content Page - Page 11

DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma

Epcoritamab With Rituximab + R² Show Durable Responses In High-risk FL Patients

Oct 17, 2023

DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma)

Subcutaneous Epcoritamab Is Well-Tolerated And Effective In Patients With R/R LBCL

Oct 05, 2023

DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma)

Epcoritamab Shows Lasting Remissions in R/R LBCL Patients

Oct 04, 2023

DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma

ITMTX Vs IVMTX For CNS Relapse In High-Risk DLBCL

Sep 27, 2023

Advertisement

DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma

Epcoritamab + R² Regimen Improves Outcomes In Patients With High‑Risk Follicular Lymphoma

Sep 26, 2023

DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma

Radiation Omission in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Sep 15, 2023

Lymphoma,MCL (Mantle Cell Lymphoma)

MRD-driven Ibrutinib Discontinuation Shows Prolonged Undetectable MRD

Sep 15, 2023

DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma

pola-R-miniCHP Shows Tolerability As A Potential Primary Treatment For Elderly DLBCL Pts

Sep 13, 2023

Previous
1
…
9
10
11
12
13
14
Next

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Newsletter

Advertisement